- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of...

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's...

The First Wave of All-Star Speakers has been Announced for Europe's Leading Festival of AI and Transformational Technology, Which is now Taking Place for the First Time in the U.S. LOS ANGELES,...

The international cinema industry conference, CinemaCon 2024 was held from April 9 to 11 at Caesars Palace, Las Vegas. As the largest and most important gathering for the worldwide motion picture...

Prophylactic administration of a selective COX-2 inhibitor reduces the volume of edema associated with photoimmunotherapy by 30-50% Reduced edema volume by 25%, even when administered post...